Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation (Nasdaq: BRKR) has announced the installation of two MuVi™ and LCS SPIM™ light-sheet microscopes at Memorial Sloan Kettering Cancer Center (MSK). Funded by Cycle for Survival, these microscopes will enhance cancer research by allowing scientists to visualize cellular and tissue characteristics. The technology is expected to improve the understanding of cancer dynamics, facilitating the development of more effective treatment methods. This advancement underscores Bruker's commitment to supporting innovative cancer research.

Bruker Corporation (Nasdaq: BRKR) has completed a majority investment in Acuity Spatial Genomics, Inc., a venture focused on advancing spatial 3D genomics. Acuity's technology, leveraging exclusive innovations from Harvard University, enables genome-wide visualization of chromatin architecture in individual cells. Its OligoFISSEQ™ and OligoFISSEQ HD™ technologies aim to provide insights into gene positioning and regulatory programs critical for understanding diseases. This investment supports Bruker's strategy in spatial biology and enhances research capabilities in oncology, neuroscience, and infectious diseases.

GlycoPath Inc. announced the closing of its seed investment round, securing Bruker Corporation (Nasdaq: BRKR) as a minority investor. The proprietary GlycoTyper™ technology captures diagnostic glycoproteins for analysis using MALDI-TOF mass spectrometry. Aimed at hepatic fibrosis, a rapidly growing disease affecting over 100 million people in the US, the technology promises improvements in early cancer detection and routine surveillance. With high throughput capabilities, it supports research and potential clinical diagnostics in various diseases.

Bruker Corporation (Nasdaq: BRKR) announces advancements in deep plasma proteomics at the virtual 17th US HUPO Conference. Key highlights include presentations on COVID-19 plasma proteomes by Professor Kirk Hansen and new software PaSER v.1.1 for real-time proteomics. Bruker's timsTOF Pro systems demonstrate enhanced sensitivity and dynamic range, crucial for large clinical cohort studies. Additionally, new consumables for structural proteomics, including the PhoX cross-linker, will be available this spring. These developments position Bruker as a leader in proteomics, enhancing diagnostic capabilities.

Bruker Corporation (Nasdaq: BRKR) announced a significant publication in Nature Communications, detailing a study on collisional cross sections (CCS) of peptides. The research, led by Professors Matthias Mann and Fabian Theis, highlights the use of deep learning to predict CCS values from peptide sequences. This advancement may enhance protein identification confidence in proteomics. The study, involving data from five organisms, generated over two million CCS values, positioning it as the most extensive dataset to date. The findings suggest potential applications in various research fields, including biomarker studies.

Bruker Corporation (Nasdaq: BRKR) announced its participation in two upcoming virtual conferences. The 10th Annual SVB Leerink Healthcare Conference will take place on February 25, 2021, at 8:40 a.m. ET, featuring Chairman Frank Laukien. Following this, the Cowen 41st Annual Health Care Conference is scheduled for March 2, 2021, at 11:10 a.m. ET, with CFO Gerald Herman. Live audio webcasts will be available on the Company's Investor Relations website, with replays for 30 days post-event.

Bruker Corporation (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.04 per share, set to be distributed on March 19, 2021, to stockholders of record as of March 5, 2021. This decision reflects the company's commitment to returning value to its shareholders while continuing to invest in innovative scientific instruments. Bruker enables significant breakthroughs in life sciences and materials research, positioning itself as a critical player in the diagnostics and analytical solutions sector.

Bruker Corporation (Nasdaq: BRKR) reported Q4 2020 revenues of $627.5 million, up 4.6% year-over-year, despite a 0.4% organic decline. GAAP operating income was $112.8 million with margins at 18.0%. Non-GAAP diluted EPS increased by 9.4% to $0.58. For FY 2020, Bruker’s revenues fell 4.1% to $1,987.5 million, with GAAP EPS at $1.02, down from $1.26 in 2019. Looking ahead, Bruker expects FY 2021 revenue growth of 11% to 13%, driven by strong organic growth and margin expansion, projecting non-GAAP EPS between $1.72 and $1.77.

Bruker Corporation (Nasdaq: BRKR) is set to announce its fourth quarter and fiscal year 2020 financial results on February 16, 2021, before market opening. A conference call will follow at 8:30 a.m. EST to discuss the results and current business trends. Investors can access the webcast via the company’s investor relations site, where a presentation will also be available. Pre-registration for the call is encouraged to streamline entry. A replay of the call will be available afterward until March 16, 2021.